[ad_1] BOTHELL, Wash .– ( BUSINESS SONGS ) – The second point above the boilerplate "About Tucatinib" should read: "ORR was 47 percent (n = 16/34)" (instead of "ORR was 47 percent …
Read More »CORRECTION and REPLACEMENT Seattle Genetics Announces Release of Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer
